Schnell, Alexandra
Huang, Linglin
Regan, Brianna M. L.
Singh, Vasundhara http://orcid.org/0000-0001-8391-8527
Vonficht, Dominik
Bollhagen, Alina http://orcid.org/0000-0003-3592-8282
Wang, Mona
Hou, Yu
Bod, Lloyd
Sobel, Raymond A. http://orcid.org/0000-0002-0477-9002
Chihara, Norio http://orcid.org/0000-0003-4499-0790
Madi, Asaf http://orcid.org/0000-0003-3441-3228
Anderson, Ana C. http://orcid.org/0000-0002-0877-2932
Regev, Aviv
Kuchroo, Vijay K. http://orcid.org/0000-0001-7177-2110
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P01AI039671, P01AI056299, R01AI144166)
Article History
Received: 21 March 2023
Accepted: 8 September 2023
First Online: 12 October 2023
Competing interests
: A.C.A. is a member of the Scientific Advisory Board for Tizona Therapeutics, Trishula Therapeutics, Compass Therapeutics, Zumutor Biologics, ImmuneOncia and Excepgen, which have interests in cancer immunotherapy. A.C.A. is also a paid consultant for iTeos Therapeutics and Larkspur Biosciences. V.K.K. is cofounder of Celsius Therapeutics, Tizona Therapeutics, Larkspur Biosciences and Bicara Therapeutics. A.C.A.’s and V.K.K.’s interests are reviewed and managed by the BWH and Partners Healthcare in accordance with their conflict of interest policies. A.R. is a cofounder of and equity holder in Celsius Therapeutics and an equity holder in Immunitas and was a Scientific Advisory Board member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov until 31 July 2020. A.R. is an employee of Genentech (member of the Roche Group) since August 2020 and has equity in Roche. The other authors declare no competing interests.